US4789733A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Purification of blood coagulation factor VIII by precipitation with sulfated polysaccharides
Assignee: National Blood Authority
•
Filing: 1986-03-06
•
Granted: 1988-12-06
•
Expires: 2006-03-06
Abstract
Abstract PCT No. PCT/GB86/00121 Sec. 371 Date Nov. 17, 1986 Sec. 102(e) Date Nov. 17, 1986 PCT Filed Mar. 6, 1986 PCT Pub. No. WO86/05190 PCT Pub. Date Sep. 12, 1986.Efficient precipitation and removal of the proteins fibrinogen and fibronectin from blood plasma fractions, expecially cryoprecipitate, while leaving high yields of blood coagulation factor VIII in the supernatant. This is achieved by the addition of at least 0.15 mg, preferably 0.3-0.9 mg, of a sulphated polysaccharide, especially heparin, per ml of buffered plasma fraction solution while maintaining the temperature of the solution during fibrinogen/fibronectin removal at more than 15 DEG C., preferably 20 DEG -35 DEG C. Lyophilised factor VIII preparation prepared from the factor VIII-rich supernatant product of the invention are suitable for heat treatment at, for example, 70 DEG C. for 24 hours to inactivate blood-born viruses without significant generation of insoluble denatured protein by-products.
Inventors
- 👤 Lowell Winkelman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 12:28
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61P; A61P7/00; A61P7/04; A61K; A61K38/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
92 words
A method of preparing a FVIII-containing preparation which includes the steps of precipitating fibrinogen and fibronectin from a buffered solution of FVIII-containing blood plasma fraction by the dissolution of a SPS, and removing the precipitate from the FVIII-containing supernatant, characterised in that the amount of SPS added to the plasma fraction is at least 0.15 mg of SPS per ml of the buffered solution and further characterised in that the temperature of the buffered solution during the precipitation and removal of the fibrinogen and fibronectin is maintained at more than 15° C.
Claim 2
Independent Claim
92 words
A method of preparing a FVIII-containing preparation which includes the steps of precipitating fibrinogen and fibronectin from a buffered solution of FVIII-containing blood plasma fraction by the dissolution of a SPS, and removing the precipitate from the FVIII-containing supernatant, characterised in that the amount of SPS added to the plasma fraction is at least 0.15 mg of SPS per ml of the buffered solution and further characterised in that the temperature of the buffered solution during the precipitation and removal of the fibrinogen and fibronectin is maintained at more than 15° C.
Claim 3
Dependent Claim
32 words
A method according to claim 1 characterised in that the amount of SPS added to the plasma fraction is not more than 3.0 mg of SPS per ml of the buffered solution.
Claim 4
Dependent Claim
30 words
A method according to claim 2 characterised in that the amount of SPS added to the plasma fraction is from 0.3 to 1.2 mg per ml of the buffered solution.
Claim 5
Dependent Claim
30 words
A method according to claim 3 characterised in that the amount of SPS added to the plasma fraction is from 0.44 to 0.88 mg per ml of the buffered solution.
Claim 6
Dependent Claim
26 words
A method according to claim 1 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at not more than 40° C.
Claim 7
Dependent Claim
26 words
A method according to claim 5 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at 20° C. to 35° C.
Claim 8
Dependent Claim
26 words
A method according to claim 6 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at 25° C. to 30° C.
Claim 9
Dependent Claim
20 words
A method according to claim 1 characterised in that the pH of the buffered solution is from 6.0 to 7.0.
Claim 10
Dependent Claim
25 words
A method according to claim 1 characterised in that the SPS is a heparinoid selected from mucopolysaccharide polysulphates, pentosan polysulphate, chondroitin sulphate and dextran sulphate.
Claim 11
Dependent Claim
20 words
A method according to claim 9 characterised in that the SPS is heparin or a soluble alkali metal salt thereof.
Claim 12
Independent Claim
128 words
A method of preparing a FVIII-containing preparation having an enhanced specific activity of FVIII, comprising the steps of precipitating fibrinogen and fibronectin from a buffered solution of cryoprecipitate at pH 6 to 8 by the dissolution of a SPS, removing the precipitate from the FVIII-containing supernatant, precipitating FVIII from the supernatant with a protein precipitant in the presence of salts, re-dissolving the FVIII precipitate, and converting the redissolved FVIII into a form which can be stored, characterised in that the amount of SPS added to the cryoprecipitate is at least 0.15 mg of SPS per ml of the buffered solution and further characterised in that the temperature of the buffered solution during the precipitation and removal of the fibrinogen and fibronectin is maintained at more than 15° C.
Claim 13
Independent Claim
128 words
A method of preparing a FVIII-containing preparation having an enhanced specific activity of FVIII, comprising the steps of precipitating fibrinogen and fibronectin from a buffered solution of cryoprecipitate at pH 6 to 8 by the dissolution of a SPS, removing the precipitate from the FVIII-containing supernatant, precipitating FVIII from the supernatant with a protein precipitant in the presence of salts, re-dissolving the FVIII precipitate, and converting the redissolved FVIII into a form which can be stored, characterised in that the amount of SPS added to the cryoprecipitate is at least 0.15 mg of SPS per ml of the buffered solution and further characterised in that the temperature of the buffered solution during the precipitation and removal of the fibrinogen and fibronectin is maintained at more than 15° C.
Claim 14
Dependent Claim
31 words
A method according to claim 11 characterised in that the amount of SPS added to the cryoprecipitate is not more than 3.0 mg of SPS per ml of the buffered solution.
Claim 15
Dependent Claim
29 words
A method according to claim 12 characterised in that the amount of SPS added to the cryoprecipitate is from 0.3 to 1.2 mg per ml of the buffered solution.
Claim 16
Dependent Claim
29 words
A method according to claim 13 characterised in that the amount of SPS added to the cryoprecipitate is from 0.44 to 0.88 mg per ml of the buffered solution.
Claim 17
Dependent Claim
26 words
A method according to claim 11 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at not more than 40° C.
Claim 18
Dependent Claim
26 words
A method according to claim 15 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at 20° C. to 35° C.
Claim 19
Dependent Claim
26 words
A method according to claim 16 characterised in that the temperature of fibrinogen and fibronectin precipitation and removal is maintained at 25° C. to 30° C.
Claim 20
Dependent Claim
20 words
A method according to claim 11 characterised in that the pH of the buffered solution is from 6.0 to 7.0.
Claim 21
Dependent Claim
25 words
A method according to claim 11 characterised in that the SPS is a heparinoid selected from mucopolysaccharide polysulphates, pentosan polysulphate, chondroitin sulphate and dextran sulphate.
Claim 22
Dependent Claim
20 words
A method according to claim 19 characterised in that the SPS is heparin or a soluble alkali metal salt thereof.
Claim 23
Dependent Claim
42 words
A method according to claim 11 characterised in that the buffered solution of cryoprecipitate is prepared by mixing with cryoprecipitate a volume of a buffer solution equal to 1% to 5% that of the blood plasma from which the cryoprecipitate is extracted.
Claim 24
Dependent Claim
30 words
A method according to claim 11 characterised in that the buffered solution of cryoprecipitate is prepared by mixing 1 part cryoprecipitate with 0.5 to 6 parts of a buffer solution.
Claim 25
Dependent Claim
30 words
A method according to claim 22 characterised in that the buffered solution of cryoprecipitate is prepared by mixing 1 part cryoprecipitate with 1 to 3 parts of the buffer solution.
References Cited (Backward Citations)
US3842061A
Cited
US3803115A
Cited
US4022758A
Cited
US4104266A
Cited
US4203891A
Cited
US4388232A
Cited
US4278594A
Cited
US4210580A
Cited
US4395396A
Cited
US4650858A
Cited
US4522751A
Cited
US4578218A
Cited
US4739039A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-06 | 1992-06-06 | 1992-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-06 | 1996-06-06 | 1996-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-06 | 2000-06-06 | 2000-12-06 | $7700.00 | Window Closed / Lapsed |